The purpose of the Organic Synthesis Core Facility (OSCF) is to provide MSKCC investigators with a fully equipped facility complete with chemistry instrumentation, GMP infrastructure, and staff with the ability to interact with non-chemists as well as chemists, in order to carry out the requested chemical synthesis and consultation. OSCF also assists investigators with pre-clinical and clinical projects. Services are focused on the following: The chemical synthesis of compounds which are not readily available. This is accomplished using established synthetic protocols or by developing new synthetic methodologies. The synthesis of assay development tools and reagents: a) fluorescently labeled compounds, b) affinity labeled compounds, and c) cross linker-tethered molecules. Cold-labeled (13C, 2H, 15N) and radio-labeled (3H, 14C, 1251, 32P, ...etc.) compounds and precursors for preclinical and clinical pharmacological studies which cannot be addressed by the shared Cyclotron- Radiochemistry Core facility. To perform large-scale -cGMP or non-cGMP- chemical syntheses of compounds with demonstrated activity in primary bioassays for preclinical, phase I and II clinical studies (i.e. Le y, Globo H, which are penta- and hexa-carbohydrate antigen vaccine constructs, Cur-61414, peptidyl-Luciferin enzyme activity beacons, and Marimastat) in order to provide sufficient quantities for continued testing. The synthesis of modified and unmodified compounds in amounts that permit their availability for in vitro and in vivo assays and for secondary assays. For example, modifications are introduced to improve solubility, affinity, and specificity. Design, synthesis, and generation of libraries of structurally related compounds based on confirmed hits; library optimization through structure-activity relationships (SAR) identified in a pharmacophore using directed library synthesis and structure-guided design in order to enhance targeting, specificity, and bioavailability while minimizing toxicity.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA008748-47
Application #
8375215
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
2013-12-31
Budget Start
2012-01-09
Budget End
2012-12-31
Support Year
47
Fiscal Year
2012
Total Cost
$180,706
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Gounder, Mrinal M; Solit, David B; Tap, William D (2018) Trametinib in Histiocytic Sarcoma with an Activating MAP2K1 (MEK1) Mutation. N Engl J Med 378:1945-1947
Mendonca, Shawn J; Sanchez, Alejandro; Blum, Kyle A et al. (2018) The association of renal cell carcinoma with gastrointestinal stromal tumors. J Surg Oncol 117:1716-1720
O'Cearbhaill, Roisin E (2018) Using PARP Inhibitors in Advanced Ovarian Cancer. Oncology (Williston Park) 32:339-43
Lichtenthal, Wendy G; Maciejewski, Paul K; Craig Demirjian, Caraline et al. (2018) Evidence of the clinical utility of a prolonged grief disorder diagnosis. World Psychiatry 17:364-365
Cottrell, T R; Thompson, E D; Forde, P M et al. (2018) Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). Ann Oncol 29:1853-1860
Pereira, PatrĂ­cia M R; Sharma, Sai Kiran; Carter, Lukas M et al. (2018) Caveolin-1 mediates cellular distribution of HER2 and affects trastuzumab binding and therapeutic efficacy. Nat Commun 9:5137
Mano, Roy; Di Natale, Renzo; Sheinfeld, Joel (2018) Current controversies on the role of retroperitoneal lymphadenectomy for testicular cancer. Urol Oncol :
Zhu, Guo; Benayed, Ryma; Ho, Caleb et al. (2018) Diagnosis of known sarcoma fusions and novel fusion partners by targeted RNA sequencing with identification of a recurrent ACTB-FOSB fusion in pseudomyogenic hemangioendothelioma. Mod Pathol :
Gollub, Marc J; Hotker, Andreas M; Woo, Kaitlin M et al. (2018) Quantitating whole lesion tumor biology in rectal cancer MRI: taking a lesson from FDG-PET tumor metrics. Abdom Radiol (NY) 43:1575-1582
Rapp, Moritz; Wiedemann, Gabriela M; Sun, Joseph C (2018) Memory responses of innate lymphocytes and parallels with T cells. Semin Immunopathol 40:343-355

Showing the most recent 10 out of 8799 publications